Plague ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Plague ' Pipeline Review, H2 2012
Published on December 2012

Report Summary


Summary

Global Markets Direct's, 'Plague - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report
provides information on the therapeutic development for Plague, complete with latest updates, and special features on late-stage and
discontinued projects. It also reviews key players involved in the therapeutic development for Plague. Plague - Pipeline Review, Half
Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites,
SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Plague.
- A review of the Plague products under development by companies and universities/research institutes based on information derived
from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Plague pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Plague.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Plague pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Content

Plague ' Pipeline Review, H2 2012 (From Slideshare) Page 1/7


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Plague Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Plague 8
Plague Therapeutics under Development by Companies 10
Plague Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Plague Therapeutics ' Products under Development by Companies 15
Plague Therapeutics ' Products under Investigation by Universities/Institutes 16
Companies Involved in Plague Therapeutics Development 17
Aradigm Corporation 17
AlphaRx, Inc. 18
Nanotherapeutics, Inc. 19
Summit Corporation plc 20
PolyMedix, Inc. 21
Mucosis B.V. 22
iBio, Inc. 23
DynPort Vaccine Company LLC 24
Tetraphase Pharmaceuticals Inc. 25
Endacea, Inc. 26
Inviragen, Inc. 27
Plague ' Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
liposomal ciprofloxacin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
gentamicin sulfate - Drug Profile 36
R&D Progress 36
PMX-30016 - Drug Profile 37
R&D Progress 37
SMT-15000 - Drug Profile 38



R&D Progress 38
Plague Vaccine - Drug Profile 39
R&D Progress 39
ciprofloxacin - Drug Profile 40
R&D Progress 40
rF1V Vaccine - Drug Profile 41
R&D Progress 41
Plague Vaccine - Drug Profile 43
R&D Progress 43
TP-271 - Drug Profile 44
R&D Progress 44
Yersinia Pestis Vaccine - Drug Profile 45
R&D Progress 45
L-97-1 Inhalation - Drug Profile 46
R&D Progress 46
doxycycline - Drug Profile 47
R&D Progress 47
Anthrax-Plague Combination Vaccine - Drug Profile 48
R&D Progress 48
Plague Therapeutics ' Drug Profile Updates 49
Plague Therapeutics ' Discontinued Products 52
Plague Therapeutics - Dormant Products 53
Plague ' Product Development Milestones 54
Featured News & Press Releases 54
Nov 19, 2012: UK Scientists Report On Efficacy Of Aradigm's Lipoquin Against Pneumonic Plague 54
Jun 05, 2008: Computer Sciences Corporation's DynPort Vaccine Company To Continue Plague Vaccine Development 55
Nov 18, 2005: Computer Sciences Corporation's DynPort Vaccine Company Reaches Milestone In Plague Vaccine Clinical Trial 55
Jan 10, 2005: Computer Sciences Corporation's DynPort Vaccine Company Enters Clinical Trial For Plague Vaccine Candidate 56



Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59

List of Tables

Number of Products Under Development for Plague, H2 2012 8
Products under Development for Plague ' Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Aradigm Corporation, H2 2012 17
AlphaRx, Inc., H2 2012 18
Nanotherapeutics, Inc., H2 2012 19
Summit Corporation plc, H2 2012 20
PolyMedix, Inc., H2 2012 21
Mucosis B.V., H2 2012 22
iBio, Inc., H2 2012 23
DynPort Vaccine Company LLC, H2 2012 24
Tetraphase Pharmaceuticals Inc., H2 2012 25
Endacea, Inc., H2 2012 26
Inviragen, Inc., H2 2012 27
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Stage and Molecule Type, H2 2012 33
Plague Therapeutics ' Drug Profile Updates 49
Plague Therapeutics ' Discontinued Products 52
Plague Therapeutics ' Dormant Products 53

List of Figures

Number of Products under Development for Plague, H2 2012 8
Products under Development for Plague ' Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10



Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 28
Assessment by Combination Products, H2 2012 29
Assessment by Route of Administration, H2 2012 30
Assessment by Stage and Route of Administration, H2 2012 31
Assessment by Molecule Type, H2 2012 32
Assessment by Stage and Molecule Type, H2 2012 33


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Plague ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Plague ' Pipeline Review, H2 2012